Patients with previous hepatitis B infection, cirrhosis or hepatocellular carcinoma need follow-up after treatment with direct-acting antivirals.
Scientists from the Indiana HTC and MicroHealth present the results of a 12-month study on the effect of HTC digital monitoring on annual bleeding rates.
NHF's Medical and Scientific Advisory Council (MASAC) issued the following three new documents, which were adopted by NHF’s Board of Directors on February 28, 2016.
The American Journal of Hematology highlights the careers of female physicians who are movers and shakers in the community.
Despite advancements in therapies, men with severe hemophilia still experience debilitating joint bleeds, lowering their quality of life.
New recombinant factor VIII therapy is expected to reduce the number of weekly prophylactic infusions for those with hemophilia A.
CSL Behring's Idelvion® stays in the bloodstream longer, potentially leading to fewer infusions.
Information in this handy guide is broken down into age groups to help nurses educate and inform the children they treat.
Recently published in the journal Blood, a team of researchers reported the successful application of gene therapy in dogs with factor VII (FVII) deficiency.
Merck's Zepatier is the latest fixed-dose oral drug taken daily to treat hepatitis C virus (HCV) infection.
eNewsletter Sign Up
Steps for Living
Victory for Women
Donate Your Car